Table A3.

Overall Survival Estimates for Patients Who Have Undergone Complete Resection for pT1-2N0M0 SCLC, Stratified by Adjuvant Therapy

Adjuvant Therapy	Events (deaths), No.	Median Survival, Months (95% CI)	5-Year Survival, % (95% CI)
None	243 of 388	42.1 (34.0 to 51.8)	40.4 (35.2 to 45.5)
Chemotherapy	188 of 354	59.8 (50.8 to 71.1)	50.0 (44.2 to 55.3)
Chemotherapy with radiation to brain	37 of 99	88.9 (72.5 to NA)	67.6 (56.9 to 76.2)
Chemotherapy with radiation to lung	52 of 87	43.8 (28.5 to 78.7)	44.5 (33.6 to 54.9)
Concurrent chemoradiation	30 of 54	56.8 (31.3 to 91.5)	48.6 (34.3 to 61.5)
Sequential chemoradiation	21 of 31	29.7 (18.7 to 95.1)	38.2 (21.5 to 54.8)
Radiation to lung	11 of 17	37.5 (19.0 to NA)	47.1 (23.0 to 68.0)

NOTE. Survival data for patients who received adjuvant radiation directed at the brain was not reported as a result of a small sample size (n < 10), in accordance with the National Cancer Data Base Participant Use File Data Use Agreement.

Abbreviations: NA, not available; SCLC, small-cell lung cancer.